Pulmonic Valve Regurgitation

• Right ventricular volume overload: Regurgitant flow during diastole increases RV preload, causing progressive RV dilatation and eccentric hypertrophy. Chronic volume overload leads to impaired RV contractility and eventually restrictive physiology. This contrasts with the pressure overload seen in pulmonary stenosis.

• Pulmonary vascular hemodynamic coupling: Increased diastolic pulmonary artery pressure (as occurs with pulmonary hypertension) increases the pressure gradient driving regurgitant flow. Elevated pulmonary vascular resistance worsens functional PR through geometric distortion of the valve annulus, creating a vicious cycle of increasing RV afterload and progressive dilatation.

• Valve apparatus dysfunction: In primary PR, structural abnormalities prevent leaflet coaptation during ventricular systole. In secondary PR, the enlarged pulmonary valve annulus (typically >40 mm) prevents normal leaflet approximation despite intact leaflet tissue. Right ventricular remodeling from any cause (dilatation, fibrosis) compounds this geometric mismatch.

Primary (Organic) Causes

• Congenital abnormalities: Tetralogy of Fallot (TOF) with previous surgical repair, pulmonary atresia, absence of pulmonic valve, endocardial cushion defects
• Rheumatic heart disease: Rare but can cause pulmonic valve involvement; usually accompanies mitral/aortic disease
• Infective endocarditis: Right-sided bacterial endocarditis particularly in IV drug users; Staphylococcus aureus most common pathogen
• Carcinoid syndrome: Serotonin-mediated fibrosis and thickening of pulmonic valve (rarely isolated; usually with tricuspid involvement)
• Blunt chest trauma: Rupture or perforation of pulmonic valve leaflets
• Myxomatous degeneration: Degenerative valve disease with prolapse and regurgitation
• Radiation therapy: Mediastinal radiation causing valve fibrosis and dysfunction

Secondary (Functional) Causes

• Pulmonary hypertension (any etiology): WHO Groups 1-5; most common cause of significant PR in clinical practice
• Right ventricular dilatation: From acute or chronic RV infarction, cardiomyopathy, atrial septal defect (ASD), left heart failure
• Severe tricuspid regurgitation: RV dilatation secondary to TR worsens PR
• Chronic lung disease: COPD, interstitial lung disease causing pulmonary hypertension

Symptoms

• Dyspnea on exertion: Due to RV dysfunction and reduced cardiac output with exercise
• Orthopnea and paroxysmal nocturnal dyspnea: In advanced disease with pulmonary edema
• Fatigue and exercise intolerance: From chronically reduced RV function
• Syncope: Rare; indicates severe RV dysfunction with critical reduction in cardiac output
• Chest discomfort: Nonspecific; may occur with RV strain
• Asymptomatic: Many patients, especially with mild-to-moderate PR, remain completely asymptomatic

Physical Examination Findings

• Prominent right ventricular parasternal lift (heave): Most characteristic finding; reflects RV hypertrophy and dilatation
• Early diastolic decrescendo murmur at left upper sternal border: Best heard with patient leaning forward at end-expiration; high-pitched, blowing quality. Graham Steell murmur when secondary to pulmonary hypertension
• Prominent "a" wave in jugular venous pulsation: Reflects reduced RV compliance
• Right ventricular S3 gallop: May be present in RV failure
• Hepatomegaly and elevated jugular venous pressure (JVP): In right heart failure
• Lower extremity edema and ascites: Advanced RV failure; cor pulmonale manifestations
• Cyanosis: May occur with right-to-left shunting if concomitant septal defect present
• Atrial fibrillation: Irregular rhythm from RV and RA dilatation
• Normal S2 or paradoxically split S2: Unlike mitral or aortic valve disease; pulmonic component may be loud if pulmonary hypertension present

Electrocardiography

• Right atrial enlargement (peaked P waves >2.5 mm in lead II)
• Right ventricular hypertrophy (tall R wave in V1, right axis deviation ≥110°)
• Right axis deviation (QRS axis >90°)
• May show atrial fibrillation with RV dilatation

Chest X-Ray

• Enlarged main pulmonary artery (suggests pulmonary hypertension)
• Cardiomegaly with RV enlargement (loss of normal concavity of left heart border)
• Prominent pulmonary vascular markings if pulmonary hypertension present
• Clear lung fields (unless concurrent left heart failure or other pulmonary pathology)

Transthoracic Echocardiography (Gold Standard Diagnostic Tool)

• Color Doppler: Diastolic jet of blood flow from pulmonary artery into RV; originates at valve annulus
• Spectral Doppler (CW): Early diastolic signal; peak velocity and shape assess severity
• Quantitative assessment:
• Mild: Jet area <5 cm² or vena contracta <3 mm
• Moderate: Jet area 5-10 cm² or vena contracta 3-6 mm, RV dilatation may begin
• Severe: Jet area >10 cm² or vena contracta >6 mm, with RV dilatation and dysfunction
• RV dimensions: RV basal diameter >42 mm suggests hemodynamically significant disease
• RV function assessment: TAPSE (tricuspid annular plane systolic excursion) <16 mm, RV S' <10 cm/s indicates RV dysfunction
• Valve anatomy: Identify structural abnormalities, vegetation (endocarditis), carcinoid plaques
• Pulmonary artery pressure estimation: Calculated from peak tricuspid regurgitation jet velocity; elevated PA pressure suggests secondary PR
• Left ventricular function: Rule out LV dysfunction as primary cause of pulmonary hypertension

Transesophageal Echocardiography

• Superior visualization of valve anatomy in patients with suboptimal TTE images
• Better assessment of endocarditis with vegetations, valve rupture, or prosthetic valve dysfunction

Cardiac Catheterization and Hemodynamics

• Right heart catheterization: Gold standard for pulmonary hypertension assessment; measure PA pressure, PCWP, CO, and calculate PVR
• Pulmonary angiography: Can visualize PR directly with contrast injection (rarely needed now with Doppler echo)
• Left heart catheterization: Assess for coronary disease contributing to RV dysfunction; exclude LV failure as etiology

Cardiac MRI

• Precise RV volume and function quantification (RVEF)
• Myocardial tissue characterization (scar, fibrosis, edema)
• Excellent for assessment of complex anatomy (particularly useful post-TOF repair)
• Valve regurgitation quantification by phase-contrast sequences

Laboratory Studies

• Brain natriuretic peptide (BNP) or NT-proBNP: Elevated in RV dysfunction; prognostic marker for disease severity
• Troponin: May be elevated with acute RV strain; nonspecific
• Thyroid function and 5-HIAA: If carcinoid syndrome suspected (associated with carcinoid PR)
• Chest CT: Assess for chronic lung disease, chronic thromboembolic disease as causes of pulmonary hypertension

Diagnostic Criteria (ACC/AHA Guidelines)

Asymptomatic Mild-to-Moderate PR without RV Dysfunction

• Conservative management: Annual clinical assessment and serial echocardiography (every 2-3 years) to monitor RV size and function
• Address underlying etiology: Treat pulmonary hypertension, manage left heart disease, optimize COPD management
• Avoid RV stressors: Limit strenuous exertion; manage anemia, infections, and arrhythmias
• No specific pharmacotherapy indicated: Diuretics not routinely used unless signs of RV failure develop

Symptomatic PR or Hemodynamically Significant PR with RV Dysfunction

• Pulmonary vasodilators (if secondary to pulmonary hypertension):
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): First-line for WHO Group 1 pulmonary hypertension; improves RV-PA coupling and reduces afterload on RV
• Endothelin receptor antagonists (ambrisentan, bosentan): Reduce PVR; used in combination therapy for severe pulmonary hypertension
• Soluble guanylate cyclase stimulators (riociguat): Emerging therapy for pulmonary hypertension
• Inhaled prostanoids (epoprostenol, iloprost, treprostinil): Reserved for advanced pulmonary hypertension

• Diuretics (loop and/or thiazide): Reduce RV preload and alleviate signs/symptoms of RV failure (peripheral edema, ascites, pulmonary congestion)
• Use cautiously to avoid excessive preload reduction and reduced cardiac output
• Typical regimen: furosemide 20-80 mg daily, uptitrate as needed

• Beta-blockers and ACE inhibitors: Limited data; consider for concurrent LV dysfunction or systemic hypertension but avoid in pulmonary hypertension where they may worsen outcomes

• Anticoagulation: Consider in specific contexts (atrial fibrillation, chronic thromboembolic disease, immobility) but not routinely recommended for PR alone

Surgical/Interventional Management

• Symptomatic patients with severe PR refractory to medical therapy
• Severe PR with RV dysfunction (RVEF <40-45%) even if asymptomatic in selected cases
• RV dilatation (basal diameter >55-60 mm) despite optimal medical therapy
• Concomitant cardiac surgery for other indications (e.g., ASD closure, left-sided valve disease)
• Endocarditis with large vegetation causing hemodynamically significant PR
• Post-TOF repair with chronic severe PR causing progressive RV dilatation

• Bioprosthetic valves: Preferred in many cases (porcine, bovine pericardial); avoid need for anticoagulation but require reoperation in 10-15 years
• Mechanical prostheses: More durable but require lifelong anticoagulation with warfarin
• Pulmonary autograft (Ross procedure): Moving patient's own aortic valve to pulmonary position; excellent hemodynamics but complex surgery with longer learning curve
• Percutaneous pulmonary valve replacement (PPVR with Melody or Sapien valves): Expanding indication; less invasive option for selected patients with prior surgical conduits

• Percutaneous pulmonary valve replacement: Emerging technology particularly suitable for patients with prosthetic conduits; good outcomes in TOF post-repair population
• Balloon pulmonary valvuloplasty: Limited role; used occasionally for congenital stenosis but rarely helpful for primary PR

Non-Pharmacological Measures

• Lifestyle modifications: Activity restriction as tolerated; avoid isometric exercise; adequate sleep and stress management
• Manage comorbidities: Treat pulmonary hypertension aggressively; optimize heart rate and rhythm control
• Pregnancy counseling: Generally well-tolerated in mild-moderate disease, but requires careful monitoring; severe PR may be contraindication
• Infection prophylaxis: Endocarditis prophylaxis no longer routinely recommended per current guidelines unless other high-risk features

Monitoring

• Clinical assessment at least annually; more frequently if symptomatic or progressive
• Echocardiographic surveillance: Every 1-2 years for severe PR; every 2-3 years for mild-moderate disease
• BNP/NT-proBNP trending: May help assess disease progression and guide therapy
• Consider repeat cardiac MRI in selected cases for precise RV volume/function quantification

Right Ventricular Dysfunction and Failure

• Progressive RV dilatation and decreased RVEF with chronic volume overload
• Loss of RV contractility and development of diastolic dysfunction
• Clinical manifestation: Peripheral edema, ascites, hepatic congestion, reduced exercise tolerance
• Management: Optimize diuretics, consider inotropic support in acute decompensation, evaluate for surgical intervention

Atrial Fibrillation

• RA dilatation from chronic RV volume/pressure overload predisposes to AF
• Loss of atrial "kick" worsens RV preload and may precipitate acute RV failure
• Management: Rate control with beta-blockers or rate-limiting calcium channel blockers; anticoagulation for stroke prevention

Pulmonary Edema

• Results from RV failure with consequent backward transmission of elevated pressures to pulmonary vasculature
• Presents acutely with dyspnea, orthopnea, PND, rales on examination
• Management: Aggressive diuretics, supplemental oxygen, treat underlying pulmonary hypertension; consider ICU monitoring

Systemic Venous Congestion and Cor Pulmonale

• Progressive RV failure leads to RA and systemic venous hypertension
• Manifests as elevated JVP, hepatomegaly, ascites, lower extremity edema
• Secondary hepatic dysfunction, protein-losing enteropathy in severe cases
• Management: Diuretics, pulmonary vasodilators if PH present, cardiac transplant consideration in end-stage disease

Tricuspid Regurgitation (Secondary)

• RV dilatation causes tricuspid annular enlargement and leaflet malcoaptation
• Worsens RV volume overload in positive feedback cycle
• Management: Optimize RV loading conditions; surgical tricuspid annuloplasty if severe and symptomatic with surgical intervention planned

Syncope and Sudden Cardiac Death

• Occurs with severe RV dysfunction and critically reduced cardiac output
• Ventricular arrhythmias (especially in post-TOF population) and bradyarrhythmias from AV nodal disease
• Management: Aggressive RV afterload reduction, evaluate for ICD implantation if EF severely depressed and arrhythmia risk high

Endocarditis (in Primary Valve Disease)

• Right-sided endocarditis, particularly common in IV drug users
• Vegetation on pulmonic valve may increase regurgitation severity acutely
• Management: Prolonged IV antibiotics (4-6 weeks); urgent surgical intervention if large vegetation, acute severe PR, or hemodynamic instability

Arrhythmia-Related Complications

• Atrial fibrillation with rapid ventricular response may precipitate acute RV failure
• Ventricular arrhythmias from RV fibrosis and scar tissue
• Management: Rate/rhythm control medications, ICD if appropriate

Progressive Pulmonary Hypertension

• **The Graham Steell murmur is the buzzword**: a high-pitched, blowing early diastolic decrescendo murmur at the left upper sternal border occurring when PR is driven by pulmonary hypertension. The classic stem is long-standing mitral stenosis with a loud P2 — the pulmonary hypertension is the link, not primary pulmonic valve disease.

• Inspiration is the discriminator: right-sided murmurs augment with inspiration (Carvallo sign) because negative intrathoracic pressure increases venous return. The most common distractor is aortic regurgitation, which shares an early diastolic decrescendo murmur but adds a widened pulse pressure and peripheral signs (water-hammer pulse, Quincke, de Musset) that PR never produces.

• Most common cause overall is functional: pulmonary hypertension of any WHO group with annular dilatation. The exam favorite for severe primary PR, however, is the young adult with repaired tetralogy of Fallot, especially after transannular patch or balloon valvuloplasty — the valve was sacrificed to relieve obstruction.

• Single best next step in a new diastolic murmur is transthoracic echocardiography; cardiac MRI follows when precise RV volumes and RVEF are needed, which the AHA/ACC adult congenital heart disease guideline emphasizes for timing pulmonic valve replacement after tetralogy repair.

• Severity and murmur loudness are decoupled: with normal PA pressures, severe ("low-pressure") PR equalizes PA and RV diastolic pressures rapidly, producing a short, soft, low-pitched murmur. A quiet murmur does not exclude severe regurgitation — judge severity by RV size and function.

• Carcinoid heart disease is the one association examiners love: serotonin-mediated plaque causes right-sided fibrosis (tricuspid regurgitation plus pulmonic disease) and requires hepatic metastases; check urinary 5-HIAA.

• Do not give endocarditis prophylaxis for native-valve PR alone — the ACC/AHA valvular heart disease guideline restricts it to prosthetic material, prior endocarditis, and specified congenital lesions.

• Trivial/physiologic PR on echo in an asymptomatic patient needs no treatment — reassurance, not vasodilators.